Boinca Therapeutics

Technology Platform - Rapa Cream: Rapamycin is an extraordinary compound isolated from the soil of Easter Island, produced by bacteria in the soil to inhibit the growth of yeast and fungi. The compound inhibits growth of human cells and has been FDA-approved as an immunosuppressant. We have conducted a pilot clinical study at Drexel with topical administration of the low-dose rapamycin cream in about thirty patients ages 40-80 across ethnicities. We have demonstrated that rapamycin does not systemically absorb when administered topically testing serum levels in patients after 6-8 months of continued daily use.

Context Therapeutics

Context Therapeutics is developing novel Sigma1 modulators based upon the work of Dr. Felix Kim. Dr. Kim discovered a novel mechanism of action for Sigma1 that has enabled the development of a suite of Sigma1 drug development tools, including biochemical and cellular screening assays, biomarkers for target engagement and patient enrichment, and animal knockout and inducible models. These tools have enabled Dr. Kim and Context to develop orally bioavailable Sigma1 modulators that are highly potent and selective across a range of indications.

Emunamedica LLC

Emunamedica LLC is a non-invasive wound diagnostics company with the only patented, clinically proven (and published) chronic wound diagnostic which is able to predict wound healing. Emunamedica’s goal is to provide wound care diagnostic support for clinicians, to generate better outcomes for patients, in a cost-effective manner for insurance companies and Medicare.

enAble Games

enAble Games is an Active Video Game (AVG) web portal for players with disabilities and their healthcare providers. It includes a suite of fun and challenging games controlled by player's bodies, and remote monitoring and therapy customization by their therapists. Flexible gaming parameters and player profiles enable each game to be adapted and adjusted locally or remotely to best fit the therapy goals of each individual player.

Kinos Medical Inc.

Kinos Medical, Inc was founded to develop and commercialize a technology poised to revolutionize total ankle replacement surgery. Utilizing hundreds of CT and MRI data sets, the Kinos IP portfolio is an anatomically & biomechanically accurate total ankle replacement platform. All systems in the comprehensive platform feature implants which restore natural joint anatomy and recreate native kinematics. The platform includes the first resurfacing implant system, which eliminates need by traditional systems to remove native bone; the first custom, patient-specific total ankle implant system; and both primary and revision systems. These market firsts are possible because the Kinos technology is based on the results of extensive imaging data, whereas other available devices over-simplify the complexities of the natural anatomy.

Currently available total ankle replacement devices fail twice as frequently as total knee systems. As a result, surgeons perform ankle fusions three times more frequently than ankle replacements. The Kinos platform will reverse these trends, improve patient outcomes and become the standard of care for patients suffering from ankle arthritis.

Lenima Field Diagnostics

Lenima offers revolutionary, groundbreaking molecular testing that can be brought to the point of care. The heart of Lenima's molecular diagnostic tests is a revolutionary piezoelectric plate sensor (PEPS) based on a novel thin crystalline material that allows unsurpassed sensitivity, simplifying the genetic testing process, permitting rapid and simultaneous testing of multiple nucleic acids including both DNAs and RNAs in a simple, elegant, portable, and low-cost format.

QLIDA

QLIDA Diagnostics, Inc. (QLIDA) which stands for quantum-dot linked immuno-detection assay, is developing portable, hand-held diagnostic tests for life threatening conditions such as infectious disease, cancer and cardiovascular diseases.

PolyCore Therapeutics

PolyCore Therapeutics’ experienced team of scientists and life sciences professionals is dedicated to developing breakthrough treatments for CNS Diseases.

Learn More

Sonnest, Inc.

Transforming Cardiac Ultrasound
Sonnest introduces Electrast – The first electrically sensitive imaging agent for assessing and monitoring the perfusion, structure and function of the heart.

Learn More

UE LifeSciences

90% of the developing world and millions of women, don't have access to breast cancer early detection. Incidence of breast cancer is expected to continue growing (after doubling in just two decades) and with that the mortality rate, mainly due to late stage detection. With innovative technologies (such as NoTouch BreastExam and iBreastExam) and a passionate team, UE LifeSciences' mission is to make the hope of early detection, a reality.

Learn More